Back

Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry

27 August 2022 (12:15 - 13:00)
Organised by:
Congress Presentation Part of: Lipids - Drug therapy 2 Drug therapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Alberto Cordero

General University Hospital Doctor Balmis of Alicante, Alicante (Spain)

6 More presentations in this session

Presentation thumbnail
Simulation study on LDL cholesterol target attainment, ASCVD events, and treatment cost of bempedoic acid in a representative German cohort of high- and very-high-CV risk patients
Doctor J. Katzmann (Leipzig, DE)
Abstract Slides
Presentation thumbnail
Effect of SLCO1B1 genotypes on statin intolerance and response to statins
Mrs L. Davis (Harefield, GB) Doctor T. Khan (Harefield, GB)
Abstract Slides
Presentation thumbnail
Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study
Doctor R. Alonso (Santiago, CL)
Abstract Slides
Presentation thumbnail
LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study
Professor K. Ray (London, GB)
Abstract Slides
Presentation thumbnail
Trends in management of cardiovascular risk factors in young adults who go on to develop coronary artery disease
Doctor D. Vikulova (Vancouver, CA)
Abstract Slides

Access the full session

Session thumbnail
Lipids - Drug therapy 2

The Event

Event poster

ESC Congress 2022

27 August 2022 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Remnant cholesterol contributes to residual lipid risk after acute coronary syndromes
28 August 2022
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025
thumbnail
Congress Session
New lipid-lowering treatment options
27 August 2022
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in reducing LDL cholesterol and triglycerides: real-life experience in a third level hospital: a descriptive, bivariate, and multivariate analysis.
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources